TG Therapeutics Inc (STU:NKB2)
€ 14.742 -0.034 (-0.23%) Market Cap: 2.35 Bil Enterprise Value: 2.26 Bil PE Ratio: 75.14 PB Ratio: 15.96 GF Score: 72/100

TG Therapeutics, Inc. - Special Call Transcript

Oct 28, 2019 / 12:30PM GMT
Release Date Price: €6.07 (+17.64%)
Operator

Greetings, and welcome to the TG Therapeutics UNITY-NHL update call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jenna Bosco. Please go ahead.

Jenna Bosco
TG Therapeutics, Inc. - VP of IR & Senior VP of Corporate Communications

Thank you. Good morning, and welcome to our conference call regarding the positive outcome from the follicular lymphoma cohort of the UNITY-NHL trial. I'm Jenna Bosco, TG's Senior Vice President of Corporate Communications, and I welcome you all to our call today.

Following our safe harbor statement, Michael Weiss, the company's Executive Chairman and Chief Executive Officer, will provide an update regarding the UNITY-NHL news announced this morning as well as offer a brief update on the company's overall standing.

Before we begin, I would like to remind everyone that various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot